Michael Schwarzschild
Co-PI (Core Leadership)
Harvard University
Dr. Michael Schwarzschild, Professor of Neurology at Harvard Medical School, is a biologist and clinical trialist focused on improving therapy for people with Parkinson’s disease. His research laboratory explores gene-environment interactions in Parkinson’s models at Massachusetts General Hospital, where his movement disorders practice is based. He leads the Parkinson Study Group, a consortium of clinical sites conducting PD trials across the US and Canada.
Recent ASAP Preprints & Published Papers
Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson's disease in the PPMI cohort
### Background α-Synuclein (α-syn) seed amplification assays (SAAs) have shown remarkable potential in diagnosing Parkinson's disease (PD). Using data from the Parkinson's Progression Markers Initiative (PPMI) cohort, we aimed to test whether baseline α-syn seeding activity and α-syn SAA kinetic parameters are associated with disease progression in sporadic PD, *LRRK2*-associated PD…
Soluble Immune Factor Profiles in Blood and CSF Associated with LRRK2 Mutations and Parkinson's Disease
**Background and Objectives**: Mutations in the Leucine-rich repeat kinase 2 (*LRRK2*) gene are one of the most common genetic causes of Parkinson's disease (PD) and are linked to immune dysregulation in both the central nervous system and periphery. However, peripheral and central profiles of soluble immune factors associated with *LRRK2* mutations and PD…
